Literature DB >> 10739373

The factor V R2 allele: risk of venous thromboembolism, factor V levels and resistance to activated protein C.

R Luddington1, A Jackson, S Pannerselvam, K Brown, T Baglin.   

Abstract

Case-control studies have yielded conflicting results regarding the relative risk of venous thromboembolism associated with the factor V R2 allele. We calculated odds ratios in 581 patients and 469 age-matched controls. The odds ratio for the R2 allele in patients relative to controls was 1.21 (95% CI 0.84 to 1.74). These results do not support the hypothesis that the R2 allele is a risk factor for venous thromboembolism. There was no relationship between factor V levels and R2 carrier status. Normalised APC sensitivity ratios were not lower in carriers of the R2 allele. In an in vitro model progressive APC resistance was observed with factor V levels of 60% and less but ratios less than 2.4 (equivalent to a normalised ratio of 0.73) did not occur until factor V levels were less than 20%. The relationship between APC resistance and factor V level was not observed in a factor VIII-independent model.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10739373

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  4 in total

1.  Evaluation of role of FV, FVIII and APLAs in the pathogenesis of APCR in FV Leiden negative DVT patients: a study in India.

Authors:  Amit Sharma; Kanwaljeet Singh; Arijit Biswas; Ravi Ranjan; Kamal Kishor; Ravi Kumar; Hareram Pandey; Vineet Kumar Kamal; Renu Saxena
Journal:  J Thromb Thrombolysis       Date:  2017-02       Impact factor: 2.300

2.  Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls.

Authors:  Benedetto Simone; Valerio De Stefano; Emanuele Leoncini; Jeppe Zacho; Ida Martinelli; Joseph Emmerich; Elena Rossi; Aaron R Folsom; Wassim Y Almawi; Pierre Y Scarabin; Martin den Heijer; Mary Cushman; Silvana Penco; Amparo Vaya; Pantep Angchaisuksiri; Gulfer Okumus; Donato Gemmati; Simona Cima; Nejat Akar; Kivilcim I Oguzulgen; Véronique Ducros; Christoph Lichy; Consuelo Fernandez-Miranda; Andrzej Szczeklik; José A Nieto; Jose Domingo Torres; Véronique Le Cam-Duchez; Petar Ivanov; Carlos Cantu-Brito; Veronika M Shmeleva; Mojka Stegnar; Dotun Ogunyemi; Suhair S Eid; Nicola Nicolotti; Emma De Feo; Walter Ricciardi; Stefania Boccia
Journal:  Eur J Epidemiol       Date:  2013-07-31       Impact factor: 8.082

3.  Acquired activated protein C resistance, thrombophilia and adverse pregnancy outcomes: a study performed in an Irish cohort of pregnant women.

Authors:  Sara Sedano-Balbás; Mark Lyons; Brendan Cleary; Margaret Murray; Geraldine Gaffney; Majella Maher
Journal:  J Pregnancy       Date:  2011-08-14

4.  American College of Medical Genetics consensus statement on factor V Leiden mutation testing.

Authors:  W W Grody; J H Griffin; A K Taylor; B R Korf; J A Heit
Journal:  Genet Med       Date:  2001 Mar-Apr       Impact factor: 8.822

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.